{"id":"NCT02168842","sponsor":"University of Rochester","briefTitle":"Efficacy of Isradipine in Early Parkinson Disease","officialTitle":"Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2018-11","completion":"2018-11","firstPosted":"2014-06-20","resultsPosted":"2020-01-14","lastUpdate":"2020-01-14"},"enrollment":336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Isradipine","otherNames":[]},{"type":"DRUG","name":"Placebo (for Isradipine)","otherNames":[]}],"arms":[{"label":"Isradipine","type":"ACTIVE_COMPARATOR"},{"label":"Placebo (for Isradipine)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.","primaryOutcome":{"measure":"Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score","timeFrame":"Baseline to 36 months of treatment","effectByArm":[{"arm":"Isradipine","deltaMin":2.99,"sd":null},{"arm":"Placebo (for Isradipine)","deltaMin":3.26,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":20},"locations":{"siteCount":54,"countries":["United States","Canada"]},"refs":{"pmids":["36865634","33460320","32227247","30741695"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":170},"commonTop":["DIZZINESS","NAUSEA","HEADACHE","NASOPHARYNGITIS","CONSTIPATION"]}}